| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| Glioblastoma is a fast-growing and aggressive brain tumor. |
| 4403- | AgNPs, | Silver Nanoparticles Decorated UiO-66-NH2 Metal-Organic Framework for Combination Therapy in Cancer Treatment |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | GL26 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | CRC, | RKO |
| 2700- | BBR, | Cell-specific pattern of berberine pleiotropic effects on different human cell lines |
| - | in-vitro, | GBM, | U343 | - | in-vitro, | GBM, | MIA PaCa-2 | - | in-vitro, | Nor, | HDFa |
| 738- | Bor, | Borax induces ferroptosis of glioblastoma by targeting HSPA5/NRF2/GPx4/GSH pathways |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | A172 | - | in-vitro, | Nor, | SVGp12 |
| 5835- | CAP, | Capsaicin and dihydrocapsaicin induce apoptosis in human glioma cells via ROS and Ca2+-mediated mitochondrial pathway |
| - | in-vitro, | GBM, | U251 |
| 5885- | CAR, | Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Nor, | HEK293 |
| 5815- | CBD, | Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents |
| - | in-vitro, | GBM, | NA |
| 4489- | Chit, | SeNPs, | Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy |
| - | in-vitro, | GBM, | U87MG |
| 1873- | DCA, | Dual-targeting of aberrant glucose metabolism in glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1851- | dietFMD, | Chemo, | Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 2497- | Fenb, | In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells |
| - | in-vitro, | GBM, | NA |
| 2260- | MF, | Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 | - | in-vivo, | NA, | NA |
| 2259- | MFrot, | MF, | Method and apparatus for oncomagnetic treatment |
| - | in-vitro, | GBM, | NA |
| 2258- | MFrot, | MF, | EXTH-68. ONCOMAGNETIC TREATMENT SELECTIVELY KILLS GLIOMA CANCER CELLS BY INDUCING OXIDATIVE STRESS AND DNA DAMAGE |
| - | in-vitro, | GBM, | GBM | - | in-vitro, | Nor, | SVGp12 |
| 186- | MFrot, | MF, | Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields |
| - | in-vitro, | GBM, | GBM | - | in-vitro, | Lung, | NA |
| 187- | MFrot, | MF, | Method for noninvasive whole-body stimulation with spinning oscillating magnetic fields and its safety in mice |
| - | in-vivo, | GBM, | NA |
| 184- | MFrot, | MF, | Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells |
| - | in-vitro, | GBM, | GBM |
| 2037- | PB, | Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria |
| - | in-vitro, | GBM, | NA | - | in-vivo, | GBM, | NA |
| 5220- | PG, | TMZ, | Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF- κ B Pathway |
| - | in-vitro, | GBM, | U87MG |
| 1948- | PL, | BNL, | Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy |
| - | in-vitro, | GBM, | NA |
| 1943- | PL, | Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells |
| - | in-vitro, | GBM, | NA | - | in-vivo, | NA, | NA |
| 2949- | PL, | Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 3011- | RosA, | Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition |
| - | in-vitro, | GBM, | SH-SY5Y | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | MCF10 |
| 4501- | SeNPs, | Mechanisms of the Cytotoxic Effect of Selenium Nanoparticles in Different Human Cancer Cell Lines |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | L929 |
| 5088- | SSE, | Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | GBM, | A172 |
| 5086- | SSE, | Sodium Selenite Induces Superoxide-Mediated Mitochondrial Damage and Subsequent Autophagic Cell Death in Malignant Glioma Cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | A172 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:27 Cells:% prod#:% Target#:1110 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid